The blocking of AR signaling can drive increased inflammation in prostate cancer cells by the induced expression of CCL2, promoting prostate cancer progression via activation of the STAT3 signaling pathway and recruitment of TAMs [42]. Here, CCL2 is linked to prostate cancer.